Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
(Date:8/28/2014)... Earlier this month, a report was ... the U.S. Air Force on the performance of vehicles ... this type of fuel made from mustard seeds, offered ... to America’s Eco friendly future. In fact, every branch ... become independent of foreign oil over the next few ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... New President/CEO and Executive Chairman Set Sights on ... Cell Biology, BOSTON, SAN DIEGO, SAN FRANCISCO ... John Mendlein have joined Fate Therapeutics as,president and ... a team of internationally recognized stem cell scientists,clinicians ...
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, ... American Red Cross to assist the victims,of Monday,s ... of the global community, we were saddened by ... province," said Jeffrey M. Yordon,chief executive officer, founder, ...
... May 14 Simcere Pharmaceutical,Group (NYSE: SCR ), a ... the patented anti-cancer biotech,product Endu in China, today announced that ... * Brean Murray Carret & Co. All ... in New York on Monday, May 19, 2008 at 2:00 ...
Cached Biology Technology:Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York 2
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... Athens, Ga. The support of peer groups ... effective breastfeeding programs, according to recent University of ... mothers in the Athens-Clarke County area determined that ... the outcomes of mothers of infants. , "Mothers ... be successful at breastfeeding," said study co-author Alex ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Breastfeeding study shows need for effective peer counseling programs 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... examination of the first direct and detailed climate record ... last remnant of Antarctic vegetation existed in a tundra ... years ago. The research, which was led by researchers ... this week and will be featured on the cover ...
... some very interesting passengers on the final mission of ... 8, 2011: thousands of bacteria. Cynthia Collins, ... is leading a series of experiments called Micro-2A that ... mission. The research seeks to understand how microgravity changes ...
... tools and techniques for achieving targeted gene delivery and ... the successful application of gene therapy to treat a ... are presented in a series of five provocative articles ... , a peer-reviewed journal published by Mary Ann Liebert, ...
Cached Biology News:Fossilized pollen reveals climate history of northern Antarctica 2Fossilized pollen reveals climate history of northern Antarctica 3Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis 2Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis 3The promise of stem cell-based gene therapy 2
... The V-106 voice-coil scanning and ... where small samples have to be ... and high resolution. It provides superior ... leadscrew drives. The mechanics (X or ...
... SearchLight® Array Analyst Software has been ... arrays. Mathematical algorithms allow the software to ... spot within each well of an ELISA ... SearchLight® Array Analyst Software has been customized ...
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
... a dual strength adhesive system which facilitates the ... adhesives on either side of the frame are ... the glass has an easy release adhesive whereas ... a stronger bond. This means that when the ...
Biology Products: